Roche has officially confirmed its strategic move to acquire specific segments of the LumiraDx group, focusing on its innovative point-of-care technology. The transaction is set to be finalised by mid-2024, after which the acquired entities will be seamlessly integrated into Roche Diagnostics.
The newly acquired solution is a groundbreaking development that consolidates various diagnostic modalities onto a unified platform. This addition will significantly enhance Roche's existing portfolio, spanning clinical chemistry, immunochemistry, coagulation, obesity, and various disease areas.
Roche expressed enthusiasm about the potential of LumiraDx's technology, emphasising its capability to integrate multiple point-of-care tests into a single, user-friendly instrument. This advancement is poised to make diagnostic testing more affordable and accessible on a global scale.
However, the successful completion of this transaction is contingent upon meeting specific conditions, including obtaining regulatory approvals. As part of the agreed-upon terms, Roche will disburse a purchase price of $295 million and may further make an additional payment of up to $55 million based on certain criteria.
Click here to read the original news story.